Cutaneous T-Cell Lymphoma News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

FDA Approves Brentuximab for Cutaneous T-Cell Lymphoma - Medscape



Medscape
 
FDA Approves Brentuximab for Cutaneous T-Cell Lymphoma 
Medscape
The US Food and Drug Administration (FDA) today approved brentuximab vedotin (Adcetris, Seattle Genetics and Takeda) for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have received prior systemic therapy. Specifically, it was ...
(Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing ... Business Wire (press release)
FDA Approves Brentuximab Vedotin for CTCL OncLive
FDA approves drug developed in Bothell to treat disfiguring blood cancer The Daily Herald
Healio  -Curetoday.com  -Specialty Pharmacy Times 
all 13 news articles » 


Cutaneous T-Cell Lymphoma - Global Clinical Trials Review, H2, 2017 - Research and Markets - Business Wire (press release)



Cutaneous T-Cell Lymphoma - Global Clinical Trials Review, H2, 2017 - Research and Markets 
Business Wire (press release)
The clinical trial report, Cutaneous T-Cell Lymphoma Global Clinical Trials Review, H2, 2017" provides an overview of Cutaneous T-Cell Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on Cutaneous T ...

and more » 


Cutaneous T-Cell Lymphoma(CTCL)- Epidemiology Forecast to 2025 - PR Newswire (press release)



Cutaneous T-Cell Lymphoma(CTCL)- Epidemiology Forecast to 2025 
PR Newswire (press release)
NEW YORK, Nov. 17, 2017 /PRNewswire/ -- DelveInsight's "Cutaneous T Cell Lymphoma(CTCL) -Epidemiology Forecast, 2025" provides an overview of the epidemiology trends of Cutaneous T Cell Lymphoma(CTCL) in seven major markets (US, France, ...

and more » 


FDA Approvals in CML, CTCL, CMV Infection, and Tumor Assay ... - OncLive



OncLive
 
FDA Approvals in CML, CTCL, CMV Infection, and Tumor Assay ... 
OncLive
Gina Columbus reports on FDA approvals in chronic myeloid leukemia, cutaneous T-cell lymphoma, cytomegalovirus infection, and a tumor assay, and clinical ...

and more » 


Takeda Receives Positive CHMP Opinion for ADCETRIS ... - Business Wire (press release)



Takeda Receives Positive CHMP Opinion for ADCETRIS ... 
Business Wire (press release)
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Produc.

and more » 


FDA Approves Adcetris for Most Common Subtypes of Cutaneous T-cell Lymphoma - Lymphoma News Today



Lymphoma News Today
 
FDA Approves Adcetris for Most Common Subtypes of Cutaneous T-cell Lymphoma 
Lymphoma News Today
The U.S. Food and Drug Administration (FDA) has approved Seattle Genetics' Adcetris (brentuximab vedotin) for the treatment of adults with the two most common subtypes of cutaneous T-cell lymphoma (CTCL) ? non-Hodgkin lymphoma that primarily ...
Seattle Genetics' Adcetris Gets FDA Nod for Label Expansion Nasdaq
Seattle Genetics wins new OK for Adcetris BioPharma Dive

all 3 news articles » 


Cutaneous T-Cell Lymphoma(CTCL) - Market Insights, Epidemiology and Market Forecast - 2025 - PR Newswire (press release)



Cutaneous T-Cell Lymphoma(CTCL) - Market Insights, Epidemiology and Market Forecast - 2025 
PR Newswire (press release)
DelveInsight's "Cutaneous T Cell Lymphoma(CTCL) - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Cutaneous T Cell Lymphoma(CTCL) for the 7MM (United States, ...

and more » 


Brentuximab Vedotin Nears European Approval for CTCL - OncLive



OncLive
 
Brentuximab Vedotin Nears European Approval for CTCL 
OncLive
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of brentuximab vedotin (Adceteris) in adults with CD30-positive cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic ...

 


Cutaneous T-Cell Lymphoma Market Overview and Scope 2017 to 2025 - Research of Market



Cutaneous T-Cell Lymphoma Market Overview and Scope 2017 to 2025 
Research of Market
Cutaneous T-Cell Lymphoma(CTCL)-Mechanism of action Insights, 2017?, report provides comprehensive insights of the ongoing therapeutic research and development across Cutaneous T-Cell Lymphoma(CTCL). The report provides a complete ...

and more » 


EU advisors back expanding use of Adcetris - PharmaTimes



PharmaTimes
 
EU advisors back expanding use of Adcetris 
PharmaTimes
Takeda's Adcetris could soon be on the market in Europe as a second-line treatment for adults with CD30-positive cutaneous T-cell lymphoma (CTCL) after regulatory advisors backed expanding the drug's scope. In Europe, doctors can currently prescribe ...